[go: up one dir, main page]

WO2010134988A1 - Systèmes, dispositifs et procédés de traitement de plaie utilisant des compositions d'hydrogel synthétiques biocompatibles - Google Patents

Systèmes, dispositifs et procédés de traitement de plaie utilisant des compositions d'hydrogel synthétiques biocompatibles Download PDF

Info

Publication number
WO2010134988A1
WO2010134988A1 PCT/US2010/001490 US2010001490W WO2010134988A1 WO 2010134988 A1 WO2010134988 A1 WO 2010134988A1 US 2010001490 W US2010001490 W US 2010001490W WO 2010134988 A1 WO2010134988 A1 WO 2010134988A1
Authority
WO
WIPO (PCT)
Prior art keywords
peg
synthetic
poly
hydrogel composition
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2010/001490
Other languages
English (en)
Inventor
Olexander Hnojewyj
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/454,593 external-priority patent/US20100297235A1/en
Application filed by Individual filed Critical Individual
Publication of WO2010134988A1 publication Critical patent/WO2010134988A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/0066—Medicaments; Biocides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0052—Mixtures of macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/602—Type of release, e.g. controlled, sustained, slow

Definitions

  • the invention relates to biocompatible materials and additives that are formulated for biomedical applications, such as wound healing and hemostasis.
  • Hemostatic agents are used to stop or control bleeding by either promoting coagulation or contacting tissue.
  • the bleeding may be caused by trauma, e.g. organ (liver, kidney) lacerations, or may be caused during surgery, e.g. cyst removal, bone bleeding, or burn operations.
  • Bleeding is usually controlled by the application of synthetic or natural sheets of gauze and GelfoamTM material or SugicelTM material. These materials, in certain procedures, are soaked with a hemostatic agent, such as thrombin or epinephrine, or formulations of sprayable fibrin adhesive. In some situations, conventional hemostasis treatments achieve clinically acceptable time. Still, there are many drawbacks .
  • fibrin adhesives and GelfoamTM are formulated with bovine thrombin and collagen, respectively, to cause the desired clotting response.
  • These biologic materials all have the potential for the transmission of bovine spongiform encephalopathy -- "Mad Cow Disease" -- to humans. Further, problems such as intraoperative blood loss, lack of hemostasis, engraftment (failure of skin grafts) , adherence, and less than satisfactory cosmetic results still persist.
  • tissue sealants act as a physical barrier to blood loss by sealing wounds and potentially aiding in healing.
  • the products are two-part liquid systems that react when mixed to create a physical barrier to blood loss. They are typically applied using two syringes coupled with a mixing chamber and delivery nozzle or tube.
  • Fibrin sealants which are the most commonly used, combine biological proteins, thrombin and fibrinogen. These require patient sensitivity testing, are difficult to prepare, and present a risk of transmitting infection. Furthermore, lot-to-lot performance is extremely inconsistent due to inherent biological variability.
  • the invention provides compositions, systems, instruments, and methods for creating families of synthetic biocompatible, hydrogel compositions that can be used in diverse therapeutic indications, among them being wound healing and the arrest or control of bleeding or leakage of fluid in body tissue.
  • synthetic it is meant that the component is chemically synthesized in the laboratory or industrially or produced using recombinant DNA technology.
  • hydrogel or “hydrogel composition” refers to a state of matter comprising a cross-linked polymer network swollen in a liquid medium. According to this aspect of the invention, the hydrogel transforms over time by physiologic mechanisms from a solid state back to a biocompatible liquid state, which can be cleared by the body. The transformation can occur, e.g., by hydrolysis of the polymer backbone.
  • One representative aspect of the invention comprises a biocompatible, synthetic, electrophilic (i.e., electron withdrawing) polymer component mixed with a biocompatible, synthetic, nucleophilic (i.e., electron donating) polymer component.
  • a biocompatible, synthetic, electrophilic (i.e., electron withdrawing) polymer component mixed with a biocompatible, synthetic, nucleophilic (i.e., electron donating) polymer component.
  • the components cross-link to form the synthetic biocompatible, hydrogel composition.
  • the electrophilic component and/or the nucleophilic component can include additive components, which can affect the physical and mechanical characteristics of the composition.
  • the system comprises a first solution, a second solution, and instructions for mixing the first and second solutions for use.
  • the first solution comprises a biocompatible, synthetic, electrophilic polymer component including a multi-arm poly (ethylene glycol) (PEG) Succinimidyl Glutarate .
  • the second solution comprises a biocompatible, synthetic, nucleophilic polymer component essentially free of human or bovine albumin and other biological molecules and including a polypeptide moiety having a number of active surface lysines of at least twenty (20) per 5000 M/W, and optionally blended with a multi-arm poly (ethylene glycol) (PEG) Amine.
  • the instructions for use comprise mixing the first and second solutions to form a synthetic hydrogel composition, and applying the synthetic hydrogel composition by topically spraying the synthetic hydrogel composition onto a targeted wound site to promote wound healing.
  • polypeptide moiety comprises Poly-L-Lysine hydrobromide .
  • the multi-arm poly (ethylene glycol) (PEG) Succinimidyl Glutarate has a functionality of four.
  • the optional multi-arm poly (ethylene glycol) (PEG) Amine (PEG-Amine) has a functionality of four.
  • the system further includes one more auxiliary component comprising salicylate-based polyanhydride-esters formulated to degrade and release salicylic acid for anti-inflammatory effect; fillers, such as glucosamine, glucosaminoglycans , and chondroitin sulfate; anti-inflamatory drugs; rapamycines and analogs, such as everolimus and biolimus,- dexamethasone ; M- prednisolone; interferon ⁇ -lb; leflunomide; mycophenolic acid; mizoribine,- cyclosporine,- tranilast; biorest; tacrolimus; taxius; pacitaxel; or taxol ; botox; lydicane; Retin A Compound; glucosamine; chondroitin sulfate; or Geldanamycin analogs 17-AAG or 17-DMAG; plasticizers, including cellulose and/or non-reactive PEG compounds, such as
  • auxiliary components that can be added include an iodinated moiety such as providone- iodine (polyvinylpyrrolidone and iodine) for antifungal/antibacterial topical application and wound healing.
  • an iodinated moiety such as providone- iodine (polyvinylpyrrolidone and iodine) for antifungal/antibacterial topical application and wound healing.
  • auxiliary components that can be added include aloe vera, also known as the medicinal alow, which contains iodine, for wound healing.
  • auxiliary components that can be added include fluorocarbons (fluorine substituded hydrocarbons) and perflurocarbons (flurocarbons in which all of the hydrogen atoms have been replaced with fluorine) , such as perfluorodecalin (CAS No. 306-94-5) and perfluorthributylamine .
  • fluro-materials can be incorporated into the hydrogel composition. Fluro-materials can be used to pressurize delivery units for the first and/or second components, to mix and deliver the hydrogel composition with 02 (oxygen) to the wound site .
  • the system further includes a dispensing unit that mixes the first and second solution and dispenses the mixture in situ through a dispensing tip.
  • the instructions for use direct use of the dispensing unit.
  • the dispensing unit is sized and configured as an integrated hand held device, or as an integrated hand held endoscopic device, or as an instrument system having mixing and dispensing units.
  • the dispensing tip is sized and configured as a needle, sprayer, or atomizer.
  • Another representative aspect of the invention provides a method for promoting wound healing.
  • the method comprises (i) providing a first solution comprising a biocompatible, synthetic, electrophilic polymer component including a multi-arm poly (ethylene glycol) (PEG) Succinimidyl Glutarate,- (ii) providing a second solution comprising a biocompatible, synthetic, nucleophilic polymer component essentially free of human or bovine albumin and other biological molecules and including a polypeptide moiety having a number of active surface lysines of at least twenty (20) per 5000 M/W, and optionally blended with a multi-arm poly(ethylene glycol)
  • the system comprise a first solution, a second solution, and instructions for mixing the first and second solutions for use.
  • the first solution comprises a biocompatible, synthetic, electrophilic polymer component including a poly (ethylene glycol) (PEG) Succinimidyl Glutarate having a functionality of four and a molecular weight of about 10,000 g/mole.
  • PEG poly (ethylene glycol)
  • Succinimidyl Glutarate having a functionality of four and a molecular weight of about 10,000 g/mole.
  • the second solution comprises a biocompatible, synthetic, nucleophilic polymer component essentially free of human or bovine albumin and other biological molecules and including Poly-L-Lysine hydrobromide having a number of active surface lysines of at least twenty (20) per 5000 M/W blended with a poly (ethylene glycol) (PEG) Amine having a functionality of four and a molecular weight of about 10,000 g/mole, wherein the weight-to-weight ratio of poly (ethylene glycol) (PEG) Amine to poly (ethylene glycol) (PEG) Succinimidyl Glutarate is selected to be about 0.7 to 1.0.
  • the instructions for use comprise mixing the first and second solutions to form a synthetic hydrogel composition, and applying the synthetic hydrogel composition by topically spraying the synthetic hydrogel composition onto a targeted wound site to promote wound healing.
  • the first solution is essential free of a buffer material.
  • the first solution comprises poly (ethylene glycol) (PEG) Succinimidyl Glutarate dissolved in Sterile Water for Injection USP (SWI) essentially free of a buffer material.
  • the second solution comprises the Poly-L-Lysine hydrobromide and poly (ethylene glycol) (PEG) Amine dissolved in HPLC-grade water for delivery that includes a buffer material.
  • the system further includes a dispensing unit that mixes the first and second solution and dispenses the mixture in situ through a dispensing tip.
  • the instructions for use direct use of the dispensing unit.
  • the dispensing unit is sized and configured as an integrated hand held device, or as an integrated hand held endoscopic device, or as an instrument system having mixing and dispensing units.
  • the dispensing tip is sized and configured as a needle, sprayer, or atomizer.
  • the system further includes one more auxiliary component comprising salicylate-based polyanhydride-esters formulated to degrade and release salicylic acid for anti- inflammatory effect; fillers, such as glucosamine, glucosaminoglycans, and chondroitin sulfate; anti-inflammatory drugs; rapamycines and analogs, such as everolimus and biolimus; dexamethasone ; M-prednisolone; interferon Y- Ib; leflunomide,- mycophenolic acid; mizoribine; cyclosporine ; tranilast; biorest; tacrolimus; taxius; pacitaxel; or taxol; botox; lydicane; Retin A Compound; glucosamine; chondroitin sulfate; or Geldanamycin analogs 17-AAG or 17-
  • auxiliary components that can be added include an iodinated moiety such as providone- iodine (polyvinylpyrrolidone and iodine) for antifungal/antibacterial topical application and wound healing.
  • an iodinated moiety such as providone- iodine (polyvinylpyrrolidone and iodine) for antifungal/antibacterial topical application and wound healing.
  • auxiliary components that can be added include aloe vera, also known as the medicinal alow, which contains iodine, for wound healing.
  • auxiliary components that can be added include fluorocarbons (fluorine substituded hydrocarbons) and perflurocarbons (flurocarbons in which all of the hydrogen atoms have been replaced with fluorine) , such as perfluorodecalin (CAS No. 306-94-5) and perfluorthributylamine . These compounds, because of their ability to dissolve large amounts of oxygen, can be applied topically, to provide extra oxygen to a specific location, to accelerate wound healing.
  • fluro-materials can be incorporated into the hydrogel composition. Fluro-materials can be used to pressurize delivery units for the first and/or second components, to mix and deliver the hydrogel composition with 02 (oxygen) to the wound site.
  • Another representative aspect of the invention provides a method for treating burn tissue comprising (i) identifying a burn tissue site; (ii) manipulating a dispensing unit to mix a first biocompatible, synthetic, electrophilic polymer solution with a second biocompatible, synthetic, nucleophilic polymer solution to form a synthetic hydrogel composition, the first solution being essentially free of human or bovine albumin and other biological molecules and comprising poly (ethylene glycol) (PEG) Succinimidyl Glutarate having a functionality of four and a molecular weight of about 10,000 g/mole, the second solution also being essentially free of human or bovine albumin and other biological molecules and including Poly-L-Lysine hydrobromide having a number of active surface lysines of at least twenty (20) per 5000 M/W, optionally blended with a poly (ethylene glycol) (PEG) Amine having a functionality of four and a molecular weight of about 10,000 g/mole ; and (iii) manipulating the dispensing unit to
  • Another representative aspect of the invention provides a method comprising (i) providing a first solution comprising a biocompatible, synthetic, electrophilic polymer component including a multi-arm poly (ethylene glycol) (PEG) Succinimidyl Glutarate; (ii) providing a second solution comprising a biocompatible, synthetic, nucleophilic polymer component essentially free of human or bovine albumin and other biological molecules and including a target amount of a polypeptide moiety having a number of active surface lysines of at least twenty (20) per 5000 M/W, the second solution, when mixed with the first solution, forming a synthetic hydrogel composition; (iii) titrating the target amount and molecular weight of a polypeptide moiety in the synthetic hydrogel composition to change the physical properties of the synthetic hydrogel composition in terms of elasticity; and/or stability during storage prior to use (shelf life) ; and/or gelation time during use; and/or degradation time after use; and (iv) instructing mixing of the first solution with
  • the polypeptide moiety is PoIy-L- Lysine hydrobromide .
  • Another representative aspect of the invention provides a method comprising (i) providing a biocompatible, synthetic, electrophilic polymer component comprising a poly (ethylene glycol) (PEG) Succinimidyl Glutarate having a functionality of four and a molecular weight of about 10,000 g/mole; (ii) providing a biocompatible, synthetic, nucleophilic polymer component comprises a poly (ethylene glycol) (PEG) Amine having a functionality of four and a molecular weight of about 10,000 g/mole that upon mixing with the electrophilic polymer component undergoes a gelation process to form a hydrogel; and (iii) delaying onset of the gelation process by blending with the nucleophilic polymer component a Poly-L-Lysine hydrobromide having a molecular weight of greater than about 4000 g/mole.
  • FIG. 1 is a diagrammatic view of a system for creating families of biocompatible, synthetic compositions having diverse therapeutic indications.
  • Fig. 2A is a representative embodiment of a delivery system for a biocompatible, synthetic composition that embodies features of the invention, the applicator tip comprising a needle.
  • Fig. 2B is a representative embodiment of a delivery system for a biocompatible, synthetic composition that embodies features of the invention, the applicator tip comprising a spray tip.
  • Fig. 2C are representative spray tips that can be used in association with the delivery device shown in Fig. 2B.
  • Fig. 3 is a representative embodiment of a delivery system for a biocompatible, synthetic composition that embodies features of the invention, the applicator tip comprising an atomizing tip.
  • Fig. 4 is a representative embodiment of a delivery system for a biocompatible, synthetic composition that embodies features of the invention, the applicator tip being carried on the end of a catheter tube for endoscopic applications.
  • Fig. 5 is a representative embodiment of a delivery system for a biocompatible, synthetic composition that embodies features of the invention, the delivery system comprising a instrument that delivers components under pressure and a hand held applicator for the pressurized components .
  • Figs. 6A to 6F Fig. 3 is a representative embodiment of a delivery system for a biocompatible, synthetic composition that embodies features of the invention, the delivery system comprising a self-contained hand-held device that includes sources of pressure to deliver reconstituted lyophilized components.
  • the delivery system comprising a self-contained hand-held device that includes sources of pressure to deliver reconstituted lyophilized components.
  • the genus platform for the system 10 includes a biocompatible, synthetic electrophilic polymer component 12 that includes a poly (ethylene glycol) (PEG) that is mixed with a biocompatible, synthetic nucleophil-ic component 14- that includes poly-L-Lysine hydrobromide .
  • the components 12 and 14 are solids that are placed in solution for delivery.
  • the two components 12 and 14, when mixed in a liquid state, are reactive.
  • the two components 12 and 14 react by cross-linking, forming a solid matrix composition 16, or hydrogel .
  • cross-linking it is meant that the hydrogel composition contains intermolecular crosslinks and optionally intramolecular crosslinks as well, arising from the formation of covalent bonds .
  • compositions 16 can be formed. These different species lend themselves to use in diverse therapeutic indications.
  • the therapeutic indications for compositions that incorporate one or more aspects of the invention include: (i) collagen restoration/replacement (e.g., topical application or void filling by injection to fill wrinkles, or for biopsy sealing); (ii) drug delivery (e.g., the delivery of glucosamine and chondroitin sulfate into the spine area or other body regions) ; (iii) stem cell or growth factor delivery (e.g., the delivery of stem cells and/or growth factors into the spine area or other body regions); (iv) tissue sealants/adhesives; (v) wound healing and the control of bleeding or fluid leakage in body tissue (e.g., lung sealing, liver lacerations, or hemostasis) ; (vi) tissue, muscle, and bone growth and regeneration; (vii) dermatology (e.g., topical cosmetic and therapeutic creams, shampoos
  • the synthetic hydrogel does not evoke swelling, fragmentation, embolization, or the coagulation cascade.
  • the synthetic hydrogel can be delivered to otherwise hard-to-reach sites, e.g., by endoscopy.
  • the synthetic hydrogel will not interfere with the intended effect of other adhesives or therapeutic compositions used in combination with the synthetic hydrogel, e.g., an adhesive that is applied to a prosthesis to fixate the prosthesis to bone or another tissue site.
  • the synthetic hydrogel aids in wound healing and hemostasis with less scarring.
  • the biocompatible, synthetic, electrophilic polymer component comprises a multi-arm poly (ethylene glycol) (PEG) Succinimidyl Glutarate having a functionality of at least three and preferably four -- or, in short hand, 4 -Arm PEG Succinimidyl Glutarate (PEG-SG) -- having a molecular weight of about 10,000 g/mole (available from Polymer Source, Inc. at www.polymersource.com).
  • PEG poly (ethylene glycol)
  • PEG-SG poly (ethylene glycol)
  • the PEG-SG is dissolved in Sterile Water for Injection USP (SWI) (available from Abbott Laboratories) for delivery.
  • SWI Sterile Water for Injection USP
  • a targeted weight of 0.25 g of PEG-SG is added to a targeted volume of 1.25 cc of Sterile Water for Injection USP and mixed. No buffering material need be added.
  • One (1) cc of the resulting HPLC Water/PEG-SG solution is housed in a sterile dispensing container.
  • An applicator unit receives the PEG-SG solution for dispensing during use, as will be described in greater detail later.
  • the nucleophilic component 14 includes a Poly-L-Lysine hydrobromide (in shorthand PoIy-L-HBr) having a molecular weight of at least 4 g/mole, with an upper limit dependent upon the physical properties desired of, e.g., 4000 g/mole, or greater than 4000 (e.g., 15,000 g/mole), and also greater than 70,000 (available from ICN Biomedicals, Inc. at www.mpbio.com).
  • the Poly-L-Lysine hydrobromide is dissolved in buffered HPLC-grade water for delivery.
  • Poly-L-Lysine hydrobromide is not characterized in terms of "functionality" as are PEG materials (i.e., 4- Arm PEG means a PEG with a functionality of four) .
  • Poly- L-Lysine hydrobromide is a polypeptide moiety (like albumin) that is characterized not by “functionality” but by reference to the number of active surface lysines, which for Poly-L-Lysine hydrobromide is at least twenty (20) per 5000 M/W.
  • the Poly-L-Lysine hydrobromide molecule is relatively long and thereby provides flexibility to the solid matrix hydrogel composition 16.
  • the Poly-L-Lysine hydrobromide molecule takes the place of human or bovine albumin and other biological molecules, which can have undesired after-effects.
  • By titrating the amount and molecular weight of Poly-L-Lysine hydrobromide in the composition one can change the physical properties of the resulting hydrogel composition in terms of, e.g., elasticity; stability during storage prior to use (shelf life); gelation time during use; and degradation time after use.
  • the nucleophilic component 14 can include a blend of Poly-L-Lysine hydrobromide, as just described, and a multi-arm poly (ethylene glycol) (PEG)
  • Amine having a functionality of at least three and preferably four -- or, in short hand, 4 -Arm PEG Amine -- having a molecular weight of about 10,000 g/mole
  • a targeted weight of 0.03 g of PEG-Amine and a target weight of 0.200 g of the Poly-L-Lysine hydrobromide are added to a target volume of 1.25 cc of HPLC-grade water (pH 9.7, with a buffer material such as tris (hydroxymethyl) aminomethae buffer) and mixed.
  • a buffer material such as tris (hydroxymethyl) aminomethae buffer
  • One (1) cc of the HPLC Water/PEG-Amine/ Poly-L-Lysine hydrobromide solution is housed in a second sterile container.
  • the dispensing unit receives the contents of second container along with the contents of the first container for mixing and dispensing during use, as will be described in greater detail later.
  • Kits may be provided to facilitate mixing of the electrophilic and nucleophilic components 12 and 14 on site at the instant of use.
  • the kits may include instructions for use, which direct the use of the composition for targeted therapeutic indications.
  • the ratio of the nucleophilic component 14 to the electrophilic component 12 is selected to be about 0.7 to 1.0. This ratio assures that there will be a greater amount of SG functional groups than amine functional groups. This selected ratio provides that substantially all amine functional groups will be reacted with the SG functional groups during the cross- linking process. It is believed that the substantial absence of unreacted amine functional groups enhances the overall biocompatibility of the resulting hydrogel .
  • the two components 12 and 14 when mixed in a liquid state, are reactive. When mixed, the two components 12 and 14 react by cross-linking, forming a solid matrix composition 16, or hydrogel. Depending upon the characteristics of the two components 12 and 14 selected, different species of matrix compositions 16 can be formed. These different species lend themselves to use in diverse therapeutic indications, as described above.
  • the formed hydrogel can comprise a foam containing the two active components 12 and 14.
  • the first component PEG-SG
  • the second component 14 PoIy-L-HBr, with or without PEG-Amine
  • the delivery system for the components 12 and 14 can be variously constructed.
  • the electrophilic component 12 and the nucleophilic component 14 can be separately prepared and housed in separate dispensing containers or vials, as previously described.
  • the PEG-SG can be placed in solution with water for injection (WFI) and contained in a first sterile vial.
  • the Poly-L-Lysine Hydrobromide can also be placed in solution with buffered water (with PEG-Amine, if desired) and contained in a second sterile vial.
  • the PEG-SG, Poly-L-Lysine Hydrobromide, and (if desired) PEG-Atnine can be lyophilized for fast mixing.
  • lyophilized component or components can take the form of microliter aliquots of solution that are lyophilized as precise and durable units of use spheres packaged inside vials or other delivery devices.
  • An example of technology that can place PEG and Poly-L-Lysine Hydrobromide into lyophilized spheres for delivery can be found at www. biolph . com .
  • desired buffers can also be added, so that, at the instance of use, all that is required is sterile water.
  • one packaging option comprises four vials (Vial 1: PEG-SG; Vial 2: WFI, for use with PEG-SG in Vial 1; Vial 3: PoIy-L-HBr, with or without PEG-Amine; and Vial 4: Buffered HPLC water, for use with the contents of Vial 3) .
  • another packaging option comprises three vials (Vial 1: PEG-SG; Vial 2: WFI for use with Vial 1 and Vial 3; Vial 3: PoIy-L-HBr, with or without PEG-Amine, and Buffer) .
  • another packaging option comprises two vials (Vial 1: PEG-SG; Vial 2 PoIy-L-HBr, with or without PEG-Amine, and Buffer; and the hospital provides WFI for Vials 1 and 2) .
  • the first and second vials are placed in a dispensing apparatus, or applicator unit 22, which is desirably disposable.
  • the dispensing unit 22 mixes the electrophilic component 12 and the nucleophilic component 14 and dispenses the mixture in situ.
  • the dispensing unit 22 can include a static mixing element (or it may not include a static mixing element) , and an appropriate delivery tip 24.
  • the dispensing unit 22 can, depending upon the dispensing environment, be sized and configured as an integrated hand held device, or as an integrated hand held endoscopic device, or as an instrument system having a dispensing unit and a mixing unit. The form, fit, and function of the dispensing unit can be optimized to match the specific requirements of the targeted indication.
  • the dispensing tip can also be sized and configured as a needle, sprayer, or atomizer.
  • the dispensing unit 22 can comprise a pair of manual syringes barrels 26 joined by a clip 28, each having a plunger 30 that are mutually joined by a joiner clip 32.
  • the vials of the -electrophilic component 12 and the nucleophilic component 14 are loaded into the syringe barrels 26.
  • a applicator joining piece 34 includes the delivery tip 24.
  • the delivery tip 24 can comprise, e.g., a needle 36 (Fig. 2A) or a spray nozzle 38 (Fig. 2B) .
  • the spray nozzle 38 can take various different forms, depending upon the manner that the hydrogel material 16 is to be applied.
  • a pressure source 40 such as a gas line, gas cylinder, or compressor can be coupled to the applicator joiner 34 via a foot switch control to introduce air into the mixed electrophilic component 12 and the nucleophilic component 14 as they are being mixed and dispensed from the applicator tip 24.
  • the gas serves to atomize the mixture 16 during application.
  • the applicator tip can be carried at the end of a catheter tube coupled to the applicator unit 22 contained in a proximal housing 44 in to provide for endoscopic spraying of the mixture to the targeted tissue site.
  • the applicator unit 22 can comprise a system having a hand held dispensing unit 46 and a remote pumping instrument 48.
  • the pumping instrument 48 receives the electrophilic component 12, the nucleophilic component 14, and pressurized air for mixing and conveyance to the dispensing unit 46.
  • the dispensing unit 46 comprises a pen-shaped device that sprays the mixture of the electrophilic component 12 and the nucleophilic component 14 onto the targeted tissue site.
  • An example of this type of system can be found at www .vivostat . com. This arrangement allows- for constant spraying over a larger tissue surface area, as well as accommodates pin point applications, such as micro-anastomosis and other difficult-to-reach areas.
  • the applicator unit 22 comprises a fully-disposable, self- contained hand-held device 50 that leverages the chemical properties of the compound to enhance usability.
  • the device 50 includes a handle 52 that pivots open into upper and lower section 70 and 72.
  • the upper section 70 receives single use, sterile component cartridges 54.
  • the lower section 72 receives pressurized air cartridges 60 with valves 62.
  • each component cartridge 54 contains lyophilized particles of the respective component 12/14 enclosed within a frangible compartment 56 next to a compartment 58 of sterile water.
  • This packaging enables the component 12/14 to be conveniently stored in lyophilized form at room temperature.
  • each frangible compartment 56 is broken, e.g., by pinching or bending the cartridge 54, to allow the sterile water to mix with and reconstitute the lyophilized component 12/14 within the cartridge 54.
  • the cartridges 54 can then be inserted into the upper section 70 (which is pivoted open) , where their distal ends couple with channels that lead to the applicator tip 24.
  • the pressurized air cartridges 60 can also be loaded into the lower section 72.
  • the upper and lower sections 70 and 72 of the handle can then be closed, as Fig. 6D shows.
  • the air canisters 60 when loaded, are coupled by valves 62 to the cartridges 54.
  • the trigger 52 opens the valves 62, to allow the pressurized air to advance pistons 64 through the cartridges 54 and convey the reconstituted components 12 and 14 to the applicator tip 24, as shown in Fig. 6E.
  • a filter 66 at the distal end of each cartridge 54 traps remnants of the frangible compartment 56 within the cartridge 54.
  • the applicator tip 24 comprises a dual- outlet nozzle (see Fig, 6E) that automatically mixes the two reactive components 12 and 14 after they have exited the applicator tip 24, so there is no pre-mixing and the tip does not clog.
  • Fig. 6F shows an alternative form for a dual-outlet nozzle that mixes components outside the nozzle.
  • a single trigger 52 can open the valves concurrently for simultaneously delivery of the components through the dual-outlet nozzle.
  • dual triggers can open the valves independently.
  • the components 12 and 14 can be conveyed simultaneously for mixing through both spray nozzles (by operating both triggers simultaneously) , or the applicator tip 24 can be intermittently cleared or purged by the delivery of an aliquot of one then the other of the components 12 and 14 through a respective one of the outlets of the dual- outlet spay nozzle (by operating the triggers independently) .
  • the two pressurized canisters 60 contained within the device 50 allow the device 50 to spray the composition 16 over the desired area without the aid of an external pressurized air instrument or other equipment that can be cumbersome, confusing, and expensive.
  • the physician can spray the synthetic hydrogel composition 16 described herein consistently over diffuse or hard to reach surface areas.
  • PEG-SG and Poly-L-Lysine Hydrobromide Preparation of the electrophilic component: A weight of 0.25 g of 4 -Arm PEG-SG (M/W 10,000 g/mole) is added to a volume of 1.25 cc of water for injection (WFI), and mixed. No buffering material is added. One (1) cc of the resulting WFI/PEG-SG solution is housed in a sterile dispensing syringe.
  • One (1) cc of the HPLC Water/Poly-L-Lysine hydrobromide solution is housed in a sterile dispensing syringe.
  • the accumulating gel strength G' (Pascals) of the mixture over time is measured on an AR2000EX Rheometer (2% strain, in oscillation mode frequency 1 Hz fast oscillation mode, 10 data points per second, time sweep, 25 mm plate, 1.5 mm gap, at 25-degrees C) .
  • the resulting graph of G' (Pascels) over time is shown below:
  • the graph shows an increase in gel strength over time.
  • the "chattering" observed at 442 seconds (2196 Pa) demonstrates excellent adhesive properties and cohesive properties in a time period well suited for treating wounds and achieving hemostasis, such as in connection with burn operations, or the coverage of large wound sites like the skin, liver, or lung sealing bleeding sites .
  • Preparation of the electrophilic component A weight of 0.25 g of 4 -Arm PEG-SG (M/W 10,000 g/mole) is added to a volume of 1.25 cc of water for injection (WFI), and mixed. No buffering material is added. One (1) cc of the resulting WFI/PEG-SG solution is housed in a sterile dispensing syringe.
  • nucleophilic component A weight of 0.13 g of PEG-Amine (M/W 10,000 g/mole) and a weight of 0.03 g of the Poly-L-Lysine hydrobromide (M/W 4,000 to 15,000 g/mole) are added to a volume of 1.25 cc of HPLC- grade water (pH 9.72, with tris (hydroxymethyl) aminomethae buffer material), and mixed.
  • HPLC- grade water pH 9.72, with tris (hydroxymethyl) aminomethae buffer material
  • the accumulating gel strength G' (Pascals) of the mixture over time is measured on an AR2000EX Rheometer (2% strain, in oscillation mode frequency 1 Hz fast oscillation mode, 10 data points per second, time sweep, 25 mm plate, 1.5 mm gap, at 25-degrees C) .
  • the resulting graph of G' (Pascels) over time is shown below, with Example 1, for comparison:
  • nucleophilic component includes a blend of PEG-Amine and Poly-L-Lysine Hydrobromide (Example 2) .
  • the "chattering" observed at about 140 seconds (2200 Pa) demonstrates excellent adhesive properties and cohesive properties in a time period well suited for treating wounds and achieving hemostasis, such as in connection with burn operations, or the coverage of large wound sites like the skin, liver, or lung sealing bleeding sites.
  • Example 2 shows that the blend of PEG- Amine and Poly-L-Lysine Hydrobromide (Example 2) exhibits a delay in gelation for about 25 seconds after mixing, which is called "open time.” During this open time, viscosity does not change.
  • the "open time” is beneficial in environments that require passage of the two components 12 and 14 through the lumen of a delivery device without gelation (e.g., in neurological or laparoscopic environments) . Passage of the components 12 and 14 can therefore occur without clogging the lumen of a delivery device. Gelation occurs later, after the components 12 and 14 have exited the delivery device 16 and reside proximal to the targeted treatment site.
  • Example 3 shows that the blend of PEG- Amine and Poly-L-Lysine Hydrobromide
  • the following graph compares the accumulation of gel strength G' (Pascals) of conventional fibrin adhesive (Baxter Healthcare Corporation) to the accumulation of gel strength G' (Pascals) of the PEG-SG and Poly-L-Lysine Hydrobromide composition of Example 1.
  • the graph shows that the Example 1 has adhesive properties and cohesive properties superior to conventional fibrin adhesives.
  • the synthetic hydrogel composition may also incorporate one or more auxiliary components that impart other mechanical and/or therapeutic benefits.
  • fast-degrading, salicylate-based polyanhydride-esters can be incorporated to degrade and release the active component (salicylic acid, or aspirin) for anti- inflammatory effect.
  • active component salicylic acid, or aspirin
  • auxiliary components that can be added include fillers, such as glucosamine, glucosaminoglycans, and chondroitin sulfate; anti-inflamatory drugs,- rapamycines and analogs, such as everolimus and biolimus or of the kind used on drug-eluting stents by Biosensors International (see.
  • dexamethasone M-prednisolone; interferon ⁇ -lb; leflunomide; mycophenolic acid; mizoribine; cyclosporine; tranilast; biorest; tacrolimus; taxius; pacitaxel; or taxol ; botox; lydicane; Retin A Compound; glucosamine; chondroitin sulfate; or Geldanamycin analogs 17 -AAG or 17 -DMAG; plasticizers , including cellulose and/or non- reactive PEG compounds, such as PEG-hydroxyl compounds; therapeutic agents such as stem cells, antibodies, antimicrobials, collagens, genes, DNA, and other therapeutic agents; hemostatic agents such as thrombin, chitosan, diatomaceous earth (CELOX Material) , silver, and/or GELFOAM ® Material; growth
  • dexamethasone M-prednisolone
  • interferon ⁇ -lb leflunomide
  • auxiliary components that can be added include an iodinated salicylic acid (ISA) molecule (including but not limited to 5-iodosalicylic acid and 3 , 5-diiodosalicylic acid) incorporated into a polyan- hydride-ester formulated to degrade and release salicylic acid for anti-inflammatory effect and release iodine for therapeutic infection prevention and wound healing.
  • ISA iodinated salicylic acid
  • auxiliary components that can be added include an iodinated moiety such as providone- iodine (polyvinylpyrrolidone and iodine) for antifungal/antibacterial topical application and wound healing.
  • an iodinated moiety such as providone- iodine (polyvinylpyrrolidone and iodine) for antifungal/antibacterial topical application and wound healing.
  • auxiliary components that can be added include aloe vera, also known as the medicinal alow, which contains iodine, for wound healing.
  • auxiliary components that can be added include fluorocarbons (fluorine substituded hydrocarbons) and perflurocarbons (flurocarbons in which all of the hydrogen atoms have been replaced with fluorine) , such as perfluorodecalin (CAS No. 306-94-5) and perfluorthributylamine .
  • fluorocarbons fluorine substituded hydrocarbons
  • perflurocarbons flurocarbons in which all of the hydrogen atoms have been replaced with fluorine
  • perfluorodecalin CAS No. 306-94-5
  • perfluorthributylamine perfluorthributylamine
  • fluro-materials can be incorporated into the hydrogel composition. Fluro-materials can be used to pressurize delivery units for the first and/or second components, to mix and deliver the hydrogel composition with 02 (oxygen) to the wound site.
  • auxiliary components may be added to either the nucleophilic or the electrophilic components 12 and 14, and could also be added to the components 12 and 14 prior to or concurrent with delivery of the components 12 and 14 to the targeted application site.
  • burn operations can be dreadful. Surgeons use a sharp device to remove the skin from the entire area of the patient's body that has been burned; bleeding signals that the tissue is healthy and can be suitable for grafting. Next, skin is harvested from a healthy, unburned area (if available) of the patient's body using depth-controlled razor-like device called a dermatome; similarly, bleeding signals that a full thickness graft has been taken. Bleeding from a donor site is diffuse, punctuate, and profuse. Bleeding from a re-use donor is even more so. Because blood loss will be substantial, hemostasis at the donor site should be controlled before pursuing wound excision.
  • the ideal situation is the use of two teams, one whose role is to obtain skin grafts and maintain hemostasis.
  • the donor skin is placed over the burn site and stapled into place.
  • the wounds are covered after each excision, possibly with an epinephrine and thrombin soaked cloth.
  • the result of this operation is excessive blood loss, and if the graft survives, then it is considered a successful burn treatment surgery.
  • the blood loss amounts to approximately 4.5 units of blood, even if completed over multiple surgeries.
  • hemorrhage control and the need for transfusion is a major medical concern.
  • Tourniquets and epinephrine-soaked sheets have been proven ineffective at controlling intraoperative blood loss. Additionally, pooling of blood or other fluids under the graft at the burn site is common, and can result in graft failure and poor cosmetic results. Fibrin sealants have been investigated for the purpose of limiting blood loss with the anticipated impact of minimizing blood loss, reducing operative time, and increasing graft success rate. Unfortunately, they leave much to be desired: the product itself has poor adhesive properties, the syringe-based applicators are difficult to use (they clog and the reaction time is too quick to dispense the product as desired) , they are very expensive, and carry the risk of disease transmission.
  • the synthetic hydrogel compositions described herein function as special purpose intraoperative and dermal adhesive compositions, providing safe, effective, and resource efficient perioperative and trauma-related tissue repair, particularly where excessive bleeding and/or impaired coagulation precludes the use of conventional modalities. Due to their excellent adhesive properties and cohesive properties, as well as the purposeful, predictable manner in which gel strength accumulates, the synthetic hydrogel compositions described herein address the aforementioned shortcomings of existing products.
  • the synthetic hydrogel compositions described herein are well suited for use as hemostatic agents in the early excision of a large burn or an extremity burn.
  • the synthetic hydrogel compositions described herein are useful as fixation agents in virtually all cases, especially if a sheet graft is planned or if the graft site involves crucial areas or particularly cosmetically important areas like the face or the hands, where any degree of graft loss results in unacceptable cosmetic deformity.
  • the synthetic hydrogel compositions described herein also offer critical advantages in pediatric cases, particularly in the reduced need for postoperative wound care. For those for whom blood transfusion is unacceptable, the employment of the synthetic hydrogel compositions described herein to reduce blood loss can literally make the difference between life and death. Further, the synthetic hydrogel compositions described herein lack the complexity of preparation and application encountered with conventional fibrin adhesives. F. Other Beneficial Properties/Indications
  • the synthetic hydrogel compositions described herein are elastic, serve as an effective sealant on wet and blood spotted tissues, and can be effectively applied as a spray and used alone or in combination with other solid matricies.
  • the synthetic hydrogel compositions described herein served as an effective elastic sealant and could be applied as a spray.
  • the synthetic hydrogel compositions described herein create an air-tight seal over a porous tissue and expands and contracts while maintaining adhesion.
  • the synthetic hydrogel compositions described herein created a seal in bloody environments.
  • the synthetic hydrogel compositions described herein adhered to wet liver tissue, sealed over a pocket of blood from the laceration that had spread over the liver surface, and maintained a seal around the blood pocket.
  • a second liver study demonstrated that the synthetic hydrogel compositions described herein could be used in combination with a solid material. Placing GELFOAM ® Material directly over the laceration, and the synthetic hydrogel compositions described herein over the solid matrix, it was demonstrated that the synthetic hydrogel compositions described herein can adhere the solid matrix to the tissue and seal the solid matrix.
  • the synthetic hydrogel compositions described herein create a mechanical bond with PTFE and Dacron graft materials. Covalent bonds cannot occur because of the non-reactive surfaces designed into these materials. However, when the synthetic hydrogel compositions described herein are first applied, they are able to partially penetrate the nooks and crannies of the irregular graft surfaces. Within seconds of application the synthetic hydrogel compositions described herein partially penetrate the natural holes found in the graft, and the synthetic hydrogel compositions described herein begin to set, thereby effectively molding themselves to the graft . G. Conclusion
  • the synthetic hydrogel compositions described herein provide diverse benefits when compared to existing technologies in this field. These benefits include (i) the synthetic hydrogel compositions described herein do not rely on a functioning coagulation cascade,- (ii) the synthetic hydrogel compositions described herein provide superior adhesion properties in "wet" tissue; (iii) the synthetic hydrogel compositions described herein make possible the use of a high-tech applicator: with a single-handed use, no pre-mixing, with delivery to large areas, which is easier to direct and control, and with interchangeable designs for anti-clog tips,- (iv) the synthetic hydrogel compositions described herein can provide delayed activation (the open time) ; (v) the synthetic hydrogel compositions described herein can provide consistency among lots, longer shelf -life at room-temperature storage, at an expensive than higher priced sealants; (vi) the synthetic hydrogel compositions described herein make possible variations in chemical formulation for target indications (e.g.

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Materials Engineering (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Selon l'invention, du glutarate de poly(éthylène glycol) (PEG) –succinimidyle à multiples bras est mélangé avec un composant polymère nucléophile, synthétique, biocompatible, essentiellement exempt d'albumine humaine ou bovine et d'autres molécules biologiques, contenant, par exemple, une fraction polypeptide ayant un nombre de lysines de surface actives d'au moins vingt (20) par 5000 M/W, qui peut également être mélangée avec une amine de poly(éthylène glycol) (PEG) à multiples bras. Le mélange forme une composition d'hydrogel synthétique. La composition d'hydrogel synthétique peut être appliquée par pulvérisation topique de la composition d'hydrogel synthétique sur un site de plaie ciblé pour favoriser la cicatrisation.
PCT/US2010/001490 2009-05-20 2010-05-20 Systèmes, dispositifs et procédés de traitement de plaie utilisant des compositions d'hydrogel synthétiques biocompatibles Ceased WO2010134988A1 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US12/454,593 2009-05-20
US12/454,593 US20100297235A1 (en) 2009-05-20 2009-05-20 Vascular puncture closure systems, devices, and methods using biocompatible synthetic hydrogel compositions
US27553409P 2009-08-31 2009-08-31
US61/275,534 2009-08-31
US33729410P 2010-02-02 2010-02-02
US61/337,294 2010-02-02

Publications (1)

Publication Number Publication Date
WO2010134988A1 true WO2010134988A1 (fr) 2010-11-25

Family

ID=43126433

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/001490 Ceased WO2010134988A1 (fr) 2009-05-20 2010-05-20 Systèmes, dispositifs et procédés de traitement de plaie utilisant des compositions d'hydrogel synthétiques biocompatibles

Country Status (1)

Country Link
WO (1) WO2010134988A1 (fr)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102911493A (zh) * 2012-09-28 2013-02-06 山东赛克赛斯药业科技有限公司 可生物降解的医用水凝胶及其制备方法与应用
CN105778124A (zh) * 2012-09-28 2016-07-20 山东赛克赛斯药业科技有限公司 可生物降解的医用水凝胶及其制备方法与应用
CN106750249A (zh) * 2016-12-26 2017-05-31 深圳迈普再生医学科技有限公司 医用水凝胶前体及其制备方法和医用水凝胶以及应用
CN109568641A (zh) * 2018-12-27 2019-04-05 山东百多安医疗器械有限公司 一种可促进伤口愈合的医用封闭胶及其制备方法
CN110433344A (zh) * 2019-08-05 2019-11-12 北京诺康达医药科技股份有限公司 一种防粘连凝胶前体、防粘连凝胶的制备方法和试剂盒
US10660945B2 (en) 2015-08-07 2020-05-26 Victor Matthew Phillips Flowable hemostatic gel composition and its methods of use
US10751444B2 (en) 2015-08-07 2020-08-25 Victor Matthew Phillips Flowable hemostatic gel composition and its methods of use
WO2021041231A1 (fr) * 2019-08-28 2021-03-04 Boston Scientific Scimed, Inc. Compositions médicales à base de polymères hydrophiles réticulables
WO2023109329A1 (fr) * 2021-12-13 2023-06-22 北京博辉瑞进生物科技有限公司 Adhésif médical pour tissu, son procédé de préparation et son utilisation
US12114843B2 (en) 2022-03-31 2024-10-15 Ethicon, Inc. Sealant applicators having mixing and spraying assemblies with malleable sections and spray tips having reduced dimensions
US12220118B2 (en) 2022-03-31 2025-02-11 Ethicon, Inc. Systems, devices and methods for reconstituting therapeutic powders, mixing precursor solutions, and expressing sealants for controlling bleeding and sealing fluid and air leaks

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040023842A1 (en) * 1998-12-04 2004-02-05 Incept Biocompatible crosslinked polymers
US20050054771A1 (en) * 1995-12-18 2005-03-10 Sehl Louis C. Adhesive tissue repair patch

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050054771A1 (en) * 1995-12-18 2005-03-10 Sehl Louis C. Adhesive tissue repair patch
US20040023842A1 (en) * 1998-12-04 2004-02-05 Incept Biocompatible crosslinked polymers

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105778124B (zh) * 2012-09-28 2017-12-05 山东赛克赛斯生物科技有限公司 可生物降解的医用水凝胶及其制备方法与应用
CN105778124A (zh) * 2012-09-28 2016-07-20 山东赛克赛斯药业科技有限公司 可生物降解的医用水凝胶及其制备方法与应用
CN102911493A (zh) * 2012-09-28 2013-02-06 山东赛克赛斯药业科技有限公司 可生物降解的医用水凝胶及其制备方法与应用
US10660945B2 (en) 2015-08-07 2020-05-26 Victor Matthew Phillips Flowable hemostatic gel composition and its methods of use
US10751444B2 (en) 2015-08-07 2020-08-25 Victor Matthew Phillips Flowable hemostatic gel composition and its methods of use
CN106750249A (zh) * 2016-12-26 2017-05-31 深圳迈普再生医学科技有限公司 医用水凝胶前体及其制备方法和医用水凝胶以及应用
CN109568641A (zh) * 2018-12-27 2019-04-05 山东百多安医疗器械有限公司 一种可促进伤口愈合的医用封闭胶及其制备方法
CN109568641B (zh) * 2018-12-27 2021-02-12 山东百多安医疗器械股份有限公司 一种可促进伤口愈合的医用封闭胶及其制备方法
CN110433344A (zh) * 2019-08-05 2019-11-12 北京诺康达医药科技股份有限公司 一种防粘连凝胶前体、防粘连凝胶的制备方法和试剂盒
WO2021041231A1 (fr) * 2019-08-28 2021-03-04 Boston Scientific Scimed, Inc. Compositions médicales à base de polymères hydrophiles réticulables
US11878092B2 (en) 2019-08-28 2024-01-23 Boston Scientific Scimed, Inc. Medical compositions based on crosslinkable hydrophilic polymers
WO2023109329A1 (fr) * 2021-12-13 2023-06-22 北京博辉瑞进生物科技有限公司 Adhésif médical pour tissu, son procédé de préparation et son utilisation
US12114843B2 (en) 2022-03-31 2024-10-15 Ethicon, Inc. Sealant applicators having mixing and spraying assemblies with malleable sections and spray tips having reduced dimensions
US12220118B2 (en) 2022-03-31 2025-02-11 Ethicon, Inc. Systems, devices and methods for reconstituting therapeutic powders, mixing precursor solutions, and expressing sealants for controlling bleeding and sealing fluid and air leaks

Similar Documents

Publication Publication Date Title
US20110104280A1 (en) Wound treatment systems, devices, and methods using biocompatible synthetic hydrogel compositions
WO2010134988A1 (fr) Systèmes, dispositifs et procédés de traitement de plaie utilisant des compositions d'hydrogel synthétiques biocompatibles
US6461325B1 (en) Fibrin delivery device and method for forming fibrin on a surface
JP4860817B2 (ja) 化学的に架橋した機械的障壁または被覆構造体をインサイチュ作成するための組成物、システムおよび方法
US5989215A (en) Fibrin delivery device and method for forming fibrin on a surface
EP1961791B1 (fr) Redox et systèmes de photo-initiateurs pour amorcer une adhérence améliorée des gels aux substrats
US6458147B1 (en) Compositions, systems, and methods for arresting or controlling bleeding or fluid leakage in body tissue
US6703047B2 (en) Dehydrated hydrogel precursor-based, tissue adherent compositions and methods of use
JP2010520799A (ja) 組織癒着防止のためのシステム、方法、および組成物
CA2215309C (fr) Systemes d'oxydoreducteur et de photoamorceur pour appretage afin d'ameliorer l'adherence de gels sur des substrats
AU2012318257B2 (en) Hemostatic compositions
US20090196928A1 (en) Biocompatible hydrogel compositions
Vaiman et al. The use of fibrin glue as hemostatic in endonasal operations: a prospective, randomized study
US20250143681A1 (en) Systems, devices and methods for reconstituting therapeutic powders, mixing precursor solutions, and expressing sealants for controlling bleeding and sealing fluid and air leaks
CN111417413B (zh) 表面富含止血促进剂的止血糊剂和用于递送的装置
JP7173447B2 (ja) ポリマー組成物、送達デバイス、及び方法
JPH0111263Y2 (fr)
KR101878769B1 (ko) 저분자 cm-1,3-베타글루칸 칼슘염 분말 지혈제
CA2435050A1 (fr) Composes, dispositifs et methodes permettant de produire in situ des barrieres mecaniques de retention ou des structures de recouvrement a base de composes chimiques reticules

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10778049

Country of ref document: EP

Kind code of ref document: A1

122 Ep: pct application non-entry in european phase

Ref document number: 10778049

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE